<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20220203190100Z</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-21-1541_h_dec_0.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 24.3.2022c(2022)1985 (final)</p></section><section><header>commission implementing decisionof 24.3.2022
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;dasatinib accordpharma - dasatinib&quot;, a medicinal 
 product for human use</header><p>(text with eea relevance) (only the spanish text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 24.3.2022
 granting marketing authorisation under regulation (ec) no 726/2004 of the european 
 parliament and of the council for &quot;dasatinib accordpharma - dasatinib&quot;, a medicinal 
 product for human use</header><p>(text with eea relevance)(only the spanish text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down union procedures for the authorisation and 
 supervision of medicinal products for human use and establishing a european medicines 
 agency
 1, and in particular article 10(2) thereof,having regard to the application submitted by accord healthcare s.l.u., on 20 june 2019, 
 under article 4(1) of regulation (ec) no 726/2004,
 having regard to the opinion of the european medicines agency, formulated on 27 january 
 2022 by the committee for medicinal products for human use,
 whereas:
 (1)
 the medicinal product &quot;dasatinib accordpharma - dasatinib&quot; complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of the 
 council of 6 november 2001 on the community code relating to medicinal products 
 for human use
 2.(2)
 it is therefore appropriate to authorise its placing on the market.
 (3)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 has adopted this decision:
 article 1the marketing authorisation provided for in article 3 of regulation (ec) no 726/2004 is granted for the medicinal product &quot;dasatinib accordpharma - dasatinib&quot;, the characteristics 
 of which are summarised in annex i to this decision. &quot;dasatinib accordpharma - dasatinib&quot; 
 shall be registered in the union register of medicinal products under number eu/1/21/1541.
 1oj l 136, 30.4.2004, p. 1.2oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>article 2the marketing authorisation concerning the medicinal product referred to in article 1 shall be subject to compliance with the conditions set out in annex ii and, in particular, with those 
 relating to manufacture and importation, control and issue.
 article 3the labelling and package leaflet concerning the medicinal product referred to in article 1 shall comply with the conditions set out in annex iii.
 article 4the period of validity of the authorisation shall be five years from the date of notification of this decision.
 article 5this decision is addressed to accord healthcare s.l.u., world trade center, moll de barcelona s/n, edifici est, 6a planta, 08039 barcelona, espa√±a.
 done at brussels, 24.3.2022
 for the commissionsandra gallina
 director-general</p></section></body></xml>